DGAP-News: Sangui BioTech International Inc.: Sangui reports increase in revenue, looking at longer Granulox market entry phase
(firmenpresse) - DGAP-News: Sangui BioTech International Inc. / Key word(s): Interim
Report
Sangui BioTech International Inc.: Sangui reports increase in revenue,
looking at longer Granulox market entry phase (with additional
features)
21.05.2013 / 08:30
---------------------------------------------------------------------
Sangui reports increase in revenue, looking at longer Granulox market entry
phase
Witten, Germany, May 21, 2013 - In the third quarter of its 2013 financial
year Sangui BioTech International, Inc., realized revenues from product
sales and royalties of above USD 33,000 (Q3 2012: USD 571). In the first
nine months of the financial year revenues amounted to more than USD 81,000
(9M 2012: USD 2,795). This can be derived from the quarterly 10-QSB report
published today. Over the nine months the company used cash in operations
of approximately USD 500,000 (9M 2012: approx. USD 461,000). It invested
almost USD 900,000 of loans in promoting the market entry of its wound
therapeutic Granulox (9M 2012: almost USD 667,000). Cash inflow from
financing activities amounted to USD 1.27 million (9M 2012: 1.05 million).
Sangui Director Hubertus Schmelz explained: 'A year ago, when Granulox was
successfully presented in the market we had hoped for a faster market
penetration. We underestimated the inertia of the health system. Today it
seems realistic to be prepared for a more extended market entry phase.' As
before successful treatments are well received by medical experts and among
patients. According to the global licensee the repurchase rate is high. In
the next step its focus will be on expanding the number of doctors actually
using the wound therapeutic, further stimulating the demand from patients
and entering new international markets.
A German language independent market research study will be made available
on www.sanguibiotech.com today. It covers the wound care market and
discusses market entry scenarios.
Sangui BioTech International, Inc. ('SGBI') is a holding company the shares
of which are being traded on the OTCQB marketplace (www.otcmarkets.com:
SGBI) and the OTC markets of the Berlin and Hamburg-Hannover stock
exchanges. Its purpose is to provide financing and access to the capital
markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a
ninety percent subsidiary of Sangui BioTech International, Inc.
For more information please contact:
Joachim Fleing
Phone: +49 (179) 7963472
Fax: +49 (2302) 915191
e-mail: fleing(at)sangui.de
End of financial news
---------------------------------------------------------------------
21.05.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
211799 21.05.2013
Themen in dieser Pressemitteilung:
sangui-biotech-international-inc-sangui-reports-increase-in-revenue
looking-at-longer-granulox-market-entry-phase
Unternehmensinformation / Kurzprofil:
Datum: 21.05.2013 - 08:30 Uhr
Sprache: Deutsch
News-ID 261760
Anzahl Zeichen: 5601
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 441 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Sangui BioTech International Inc.: Sangui reports increase in revenue, looking at longer Granulox market entry phase"
steht unter der journalistisch-redaktionellen Verantwortung von
Sangui BioTech International Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
